| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.22 | 5e-07 |
| mRNA | paclitaxel | CCLE | pan-cancer | AAC | 0.18 | 0.0001 |
| mRNA | Irinotecan | CCLE | pan-cancer | AAC | 0.21 | 0.0001 |
| mRNA | IOX2 | GDSC1000 | pan-cancer | AAC | 0.12 | 0.0003 |
| mRNA | Docetaxel | GDSC1000 | pan-cancer | AAC | 0.11 | 0.0003 |
| mRNA | tacedinaline | CTRPv2 | pan-cancer | AAC | -0.13 | 0.0008 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | Nutlin-3 | CTRPv2 | pan-cancer | AAC | -0.11 | 0.0009 |
| mRNA | BRD-K07442505 | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |
| mRNA | PDMP | CTRPv2 | pan-cancer | AAC | -0.12 | 0.001 |